In the last trading session, 1.11 million NeuroSense Therapeutics Ltd (NASDAQ:NRSN) shares changed hands as the company’s beta touched 1.61. With the company’s per share price at $2.13 changed hands at $0.23 or 12.11% during last session, the market valuation stood at $51.10M. NRSN’s last price was a premium, traded about 10.8% off its 52-week high of $1.90. The share price had its 52-week low at $0.51, which suggests the last value was 76.06% up since then.

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) trade information

Instantly NRSN was in green as seen at the end of in last trading. With action 22.41%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 77.50%, with the 5-day performance at 22.41% in the green. However, in the 30-day time frame, NeuroSense Therapeutics Ltd (NASDAQ:NRSN) is 104.06% up.

NeuroSense Therapeutics Ltd (NRSN) estimates and forecasts

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.71%. The 2025 estimates are for NeuroSense Therapeutics Ltd earnings to increase by 16.83%, but the outlook for the next 5-year period is at 27.32% per year.

NeuroSense Therapeutics Ltd (NASDAQ:NRSN)’s Major holders

MEITAV INVESTMENT HOUSE LTD holds the second largest percentage of outstanding shares, with 0.2597% or 40000.0 shares worth $44800.0 as of 2024-06-30.

With 15.87 shares estimated at $33803.0 under it, the former controlled 0.07% of total outstanding shares.